Dry Eye Syndromes, Meibomian Gland Dysfunction
Conditions
Keywords
intense pulsed light
Brief summary
Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology. Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published. A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019. The investigators present a retrospective study on our first clinical results.
Interventions
DEVICEintense pulsed light (usual practice)
collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
Sponsors
Quantel Medical
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment. * patient affiliated with a social security organization
Exclusion criteria
* patient with incomplete follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lacrydiag in current clinical practice | 6 months | The LacryDiag ocular surface analyzer is used for the diagnosis of dry eyes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ocular Surface Disease Index questionnaire | 6 months | measured in current clinical practice. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. |
| Slit lamp Photography x16 and x25 | 6 months | in current clinical practice |
| collection of adverse events | 6 months | -data concerning the safety: presence or absence of adverse events during treatment or afterwards (burns, tingling, redness of skin ...) |
| Break-up time Test | 6 months | measured in current clinical practice. The measurement of the tear film rupture time determines the stability of the tear film, i.e. the degree of humidification of the eyes. |
| Schirmer Test | 6 months | measured in current clinical practice. Determination of the quantity of tears produced. |
| Oxford Score | 6 months | measured in current clinical practice. The Oxford score is used to assess epithelial damage to the cornea and conjunctiva. |
Countries
France
Outcome results
None listed